Orthofix Medical Inc. (OFIX) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 10, 2026
Orthofix Medical Inc. (OFIX)
A forensic read on Orthofix Medical Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
0.9
Distress distance
Clean
Earnings quality
5
Forensic signals
-6.7
P / E (ttm)
-20.5%
ROE
$419M
Market cap
0.00%
Dividend yield
2.9%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Orthofix Medical Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 0.9, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-10.8%
FY2025
Return on invested capital.Return on invested capital is -10.8% in the latest fiscal year and slipping from -3% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
3% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 3% of revenue in FY2025 — about $0.72 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 3.2% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
149% of FCF
FY2016
Shareholder returns.Returned $63M to shareholders (buybacks + dividends) in FY2016 — 149% of free cash flow. More than free cash flow generated — and beyond operating cash too, so the extra is coming from debt or cash reserves, which isn't sustainable indefinitely.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +97% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +25.5%/yr figure isn't a real buyback/dilution read here.
$12M
FY2021–FY2021
Goodwill impairments.Took $12M of goodwill writedowns across 1 year (FY2021 ($12M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$822.3M
Revenue Growth YoY+2.9%
Revenue CAGR (3yr)+21.3%
Net Margin-11.2%
Free Cash Flow-$1.3M
Return on Equity-20.5%
Debt / Equity0.35x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Orthofix Medical Inc.'s actual 10-K/10-Q/8-K filings?